King extends its offer for Alpharma
Executive Summary
King Pharmaceuticals will extend its tender offer for shares of Alpharma to Nov. 21. Its second offer of $37/share was rejected Sept. 26, with CEO Dean Mitchell citing the offer as "financially inadequate." The offer was a step up from King's original $33/share offering (1"The Pink Sheet," Sept. 29, 2008, p. 29). But in a letter to shareholders at the end of September, Mitchell said he believes other offers or alternatives to King's may emerge, providing shareholders with greater value than $37/share, and that the company has received expressions of interest from multiple parties
You may also be interested in...
Credit Woes Hit Pharma
The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.
King’s Higher Bid For Alpharma Still No Ace, Board Says
"Multiple parties" have indicated interest in a business combination with Alpharma, the company's board of directors said in a letter to shareholders Sept. 26, urging them to reject King's $1.6 billion hostile bid for the company
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.